Meridian Bioscience (VIVO) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
Net Sales: 47M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: -100.0%
Financial Fact:
Net Sales: 47M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Meridian Bioscience (Nasdaq: VIVO) reported Q4 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $48 million versus the consensus estimate of $46.2 million.
Meridian Bioscience reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Renasant Corp. (RNST) Tops Q1 EPS by 3c
- Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
